vs

Side-by-side financial comparison of FRIEDMAN INDUSTRIES INC (FRD) and Harmony Biosciences Holdings, Inc. (HRMY). Click either name above to swap in a different company.

Harmony Biosciences Holdings, Inc. is the larger business by last-quarter revenue ($243.8M vs $168.0M, roughly 1.5× FRIEDMAN INDUSTRIES INC). Harmony Biosciences Holdings, Inc. runs the higher net margin — 9.2% vs 1.8%, a 7.4% gap on every dollar of revenue. On growth, FRIEDMAN INDUSTRIES INC posted the faster year-over-year revenue change (78.6% vs 21.1%). Harmony Biosciences Holdings, Inc. produced more free cash flow last quarter ($126.0M vs $-6.3M). Over the past eight quarters, Harmony Biosciences Holdings, Inc.'s revenue compounded faster (25.6% CAGR vs 13.3%).

Hellman & Friedman (H&F) is an American private equity firm founded in 1984 by Warren Hellman and Tully Friedman that makes investments primarily through leveraged buyouts as well as growth capital investments. It has focused its efforts on several core target industries including media, financial services, professional services and information services.

Harmony Biosciences Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare neurological and central nervous system disorders. Its primary market is the United States, with its core product serving patients living with narcolepsy and other sleep-related CNS conditions across adult and pediatric segments.

FRD vs HRMY — Head-to-Head

Bigger by revenue
HRMY
HRMY
1.5× larger
HRMY
$243.8M
$168.0M
FRD
Growing faster (revenue YoY)
FRD
FRD
+57.4% gap
FRD
78.6%
21.1%
HRMY
Higher net margin
HRMY
HRMY
7.4% more per $
HRMY
9.2%
1.8%
FRD
More free cash flow
HRMY
HRMY
$132.4M more FCF
HRMY
$126.0M
$-6.3M
FRD
Faster 2-yr revenue CAGR
HRMY
HRMY
Annualised
HRMY
25.6%
13.3%
FRD

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
FRD
FRD
HRMY
HRMY
Revenue
$168.0M
$243.8M
Net Profit
$3.0M
$22.5M
Gross Margin
2.3%
71.9%
Operating Margin
2.3%
15.8%
Net Margin
1.8%
9.2%
Revenue YoY
78.6%
21.1%
Net Profit YoY
364.1%
-54.6%
EPS (diluted)
$0.43
$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FRD
FRD
HRMY
HRMY
Q4 25
$168.0M
$243.8M
Q3 25
$152.4M
$239.5M
Q2 25
$134.8M
$200.5M
Q1 25
$184.7M
Q4 24
$94.1M
$201.3M
Q3 24
$106.8M
$186.0M
Q2 24
$114.6M
$172.8M
Q1 24
$154.6M
Net Profit
FRD
FRD
HRMY
HRMY
Q4 25
$3.0M
$22.5M
Q3 25
$2.2M
$50.9M
Q2 25
$5.0M
$39.8M
Q1 25
$45.6M
Q4 24
$-1.2M
$49.5M
Q3 24
$-675.0K
$46.1M
Q2 24
$2.6M
$11.6M
Q1 24
$38.3M
Gross Margin
FRD
FRD
HRMY
HRMY
Q4 25
2.3%
71.9%
Q3 25
1.9%
75.1%
Q2 25
5.2%
81.0%
Q1 25
82.7%
Q4 24
73.0%
Q3 24
-0.2%
77.0%
Q2 24
-1.2%
81.4%
Q1 24
82.2%
Operating Margin
FRD
FRD
HRMY
HRMY
Q4 25
2.3%
15.8%
Q3 25
1.9%
27.3%
Q2 25
5.2%
24.0%
Q1 25
30.4%
Q4 24
-1.3%
27.7%
Q3 24
-0.2%
33.2%
Q2 24
-1.2%
12.4%
Q1 24
33.7%
Net Margin
FRD
FRD
HRMY
HRMY
Q4 25
1.8%
9.2%
Q3 25
1.5%
21.2%
Q2 25
3.7%
19.8%
Q1 25
24.7%
Q4 24
-1.2%
24.6%
Q3 24
-0.6%
24.8%
Q2 24
2.2%
6.7%
Q1 24
24.8%
EPS (diluted)
FRD
FRD
HRMY
HRMY
Q4 25
$0.43
$0.38
Q3 25
$0.32
$0.87
Q2 25
$0.71
$0.68
Q1 25
$0.78
Q4 24
$-0.17
$0.85
Q3 24
$-0.10
$0.79
Q2 24
$0.37
$0.20
Q1 24
$0.67

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FRD
FRD
HRMY
HRMY
Cash + ST InvestmentsLiquidity on hand
$3.0M
$775.3M
Total DebtLower is stronger
$163.7M
Stockholders' EquityBook value
$142.2M
$870.2M
Total Assets
$311.9M
$1.3B
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FRD
FRD
HRMY
HRMY
Q4 25
$3.0M
$775.3M
Q3 25
$4.6M
$672.6M
Q2 25
$2.1M
$565.3M
Q1 25
$507.0M
Q4 24
$1.1M
$467.2M
Q3 24
$2.5M
$410.5M
Q2 24
$4.1M
$346.9M
Q1 24
$372.4M
Total Debt
FRD
FRD
HRMY
HRMY
Q4 25
$163.7M
Q3 25
$168.5M
Q2 25
$172.1M
Q1 25
$175.7M
Q4 24
$179.3M
Q3 24
$182.8M
Q2 24
$186.4M
Q1 24
$190.0M
Stockholders' Equity
FRD
FRD
HRMY
HRMY
Q4 25
$142.2M
$870.2M
Q3 25
$139.3M
$835.1M
Q2 25
$137.3M
$773.1M
Q1 25
$720.5M
Q4 24
$127.3M
$659.2M
Q3 24
$128.8M
$596.8M
Q2 24
$129.7M
$538.6M
Q1 24
$515.4M
Total Assets
FRD
FRD
HRMY
HRMY
Q4 25
$311.9M
$1.3B
Q3 25
$311.3M
$1.2B
Q2 25
$219.1M
$1.1B
Q1 25
$1.1B
Q4 24
$210.3M
$999.2M
Q3 24
$209.2M
$928.1M
Q2 24
$222.8M
$858.4M
Q1 24
$847.0M
Debt / Equity
FRD
FRD
HRMY
HRMY
Q4 25
0.19×
Q3 25
0.20×
Q2 25
0.22×
Q1 25
0.24×
Q4 24
0.27×
Q3 24
0.31×
Q2 24
0.35×
Q1 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FRD
FRD
HRMY
HRMY
Operating Cash FlowLast quarter
$-4.7M
$126.2M
Free Cash FlowOCF − Capex
$-6.3M
$126.0M
FCF MarginFCF / Revenue
-3.8%
51.7%
Capex IntensityCapex / Revenue
1.0%
0.0%
Cash ConversionOCF / Net Profit
-1.56×
5.61×
TTM Free Cash FlowTrailing 4 quarters
$347.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FRD
FRD
HRMY
HRMY
Q4 25
$-4.7M
$126.2M
Q3 25
$434.0K
$108.7M
Q2 25
$15.5M
$79.3M
Q1 25
$34.0M
Q4 24
$75.6M
Q3 24
$70.5M
Q2 24
$-6.1M
$42.6M
Q1 24
$31.1M
Free Cash Flow
FRD
FRD
HRMY
HRMY
Q4 25
$-6.3M
$126.0M
Q3 25
$-2.0M
$108.7M
Q2 25
$13.7M
$79.3M
Q1 25
$33.9M
Q4 24
$75.0M
Q3 24
$70.5M
Q2 24
$-7.1M
$42.0M
Q1 24
$31.1M
FCF Margin
FRD
FRD
HRMY
HRMY
Q4 25
-3.8%
51.7%
Q3 25
-1.3%
45.4%
Q2 25
10.2%
39.6%
Q1 25
18.3%
Q4 24
37.3%
Q3 24
37.9%
Q2 24
-6.2%
24.3%
Q1 24
20.1%
Capex Intensity
FRD
FRD
HRMY
HRMY
Q4 25
1.0%
0.0%
Q3 25
1.6%
0.0%
Q2 25
1.3%
0.0%
Q1 25
0.1%
Q4 24
0.3%
Q3 24
0.0%
Q2 24
0.9%
0.4%
Q1 24
0.0%
Cash Conversion
FRD
FRD
HRMY
HRMY
Q4 25
-1.56×
5.61×
Q3 25
0.19×
2.14×
Q2 25
3.08×
1.99×
Q1 25
0.75×
Q4 24
1.53×
Q3 24
1.53×
Q2 24
-2.36×
3.68×
Q1 24
0.81×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FRD
FRD

Prime Coil$152.0M90%
Manufactured Pipe$14.9M9%
Customer Owned$1.1M1%

HRMY
HRMY

Segment breakdown not available.

Related Comparisons